346 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Avalon Capital Management

Avalon Capital Management acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 346 shares of the medical research company’s stock, valued at approximately $201,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Mutual Advisors LLC increased its stake in Thermo Fisher Scientific by 6.4% during the third quarter. Mutual Advisors LLC now owns 2,023 shares of the medical research company’s stock worth $1,024,000 after acquiring an additional 122 shares during the last quarter. Bamco Inc. NY increased its stake in Thermo Fisher Scientific by 5.0% during the third quarter. Bamco Inc. NY now owns 23,160 shares of the medical research company’s stock worth $11,723,000 after acquiring an additional 1,101 shares during the last quarter. Morningstar Investment Services LLC increased its stake in Thermo Fisher Scientific by 21.9% during the third quarter. Morningstar Investment Services LLC now owns 764 shares of the medical research company’s stock worth $384,000 after acquiring an additional 137 shares during the last quarter. Gotham Asset Management LLC increased its stake in Thermo Fisher Scientific by 47.5% during the third quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock worth $1,343,000 after acquiring an additional 855 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its stake in Thermo Fisher Scientific by 54.3% during the third quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock worth $6,128,000 after acquiring an additional 4,260 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.4 %

NYSE TMO traded up $2.22 during trading on Friday, reaching $553.00. 6,150,885 shares of the company’s stock were exchanged, compared to its average volume of 1,473,906. The stock has a market cap of $211.09 billion, a P/E ratio of 35.47, a price-to-earnings-growth ratio of 2.58 and a beta of 0.79. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a 50 day moving average price of $574.84 and a two-hundred day moving average price of $563.04. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The disclosure for this sale can be found here. In the last three months, insiders sold 22,000 shares of company stock valued at $12,532,780. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Evercore ISI lifted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $607.06.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.